HLB Pharmaceutical has postponed the schedule for its ongoing paid-in capital increase, conducted through a general public offering of unsubscribed shares after shareholder allotment, by approximately one month. According to HLB Pharmaceutical's corrected disclosure on the paid-in capital increase decision on the 18th, key dates including the new share allotment record date, subscription date, payment date, and scheduled listing date for new shares have been changed. However, existing plans such as the number of shares to be issued and the amount of funds to be raised remain unchanged and will proceed as planned.

This paid-in capital increase will involve the issuance of 10,762,332 common shares. The planned issue price per share is KRW 11,150, and based on this, approximately KRW 120 billion in funds will be raised. The raised funds will be allocated to KRW 55 billion for facility investment, approximately KRW 50 billion for operating capital, and KRW 15 billion for debt repayment. Based on the new share allotment record date, existing shareholders will be allotted 0.3281321329 new shares per existing share, representing a capital increase ratio of 32.81%.

• The detailed schedule changes under the corrected disclosure are as follows.
• New share allotment record date: July 1 → August 5
• Existing shareholders' subscription date: August 10-11 → September 10-11
• Payment date: August 19 → September 18
• Scheduled listing date for new shares: September 1 → October 7
• Scheduled date for confirming the final issue price and end date of short-selling restriction period: August 5 → September 7

Meanwhile, the general public offering subscription is scheduled to take place from September 15 to 16, 2026. Additionally, the subscription warrants will be listed from August 26 to September 1, 2026, and will be delisted on September 2 of the same month.

The lead underwriter for this paid-in capital increase is Korea Investment & Securities, Hana Securities is serving as co-lead manager, and Hanyang Securities is acting as the underwriting firm.